Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Dyne Therapeutics, Inc. (DYN) had Normalized Income after Taxes of $-120.85M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-120.85M |
|
-- |
|
-- |
|
$125.28M |
|
$-125.28M |
|
$4.42M |
|
$-120.85M |
|
$-120.85M |
|
$-120.85M |
|
$-120.85M |
|
$-120.85M |
|
|
Normalized Income after Taxes |
$-120.85M |
$-125.28M |
|
$-125.00M |
|
165.04M |
|
165.04M |
|
$-0.73 |
|
$-0.73 |
|
| Balance Sheet Financials | |
$1.02B |
|
$23.68M |
|
$58.92M |
|
$1.08B |
|
$51.25M |
|
$149.38M |
|
$163.65M |
|
$214.90M |
|
$865.06M |
|
$865.05M |
|
$865.05M |
|
165.20M |
|
| Cash Flow Statement Financials | |
$-144.92M |
|
$-2.39M |
|
$7.06M |
|
$895.74M |
|
$755.49M |
|
$-140.25M |
|
$13.08M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
19.92 |
|
-- |
|
-- |
|
0.15 |
|
0.18 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-145.14M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-13.97% |
|
-13.97% |
|
-11.19% |
|
-11.91% |
|
$5.24 |
|
$-0.88 |
|
$-0.88 |
|